abstract_id,investigational_product,title,modality,indication,phase_number,route_of_administration,mechanism_of_action,target,countries_of_sites,control_arm,treatment_arm,study_population,study_size,component_interventions,regimen_type,line_of_therapy,comparator,trial_design_and_comparator
3764,tislelizumab,An exploratory study of neoadjuvant tislelizumab combined with TP regimen for the comprehensive treatment of resectable locally advanced oral squamous cell carcinoma.,immunotherapy,resectable locally advanced oral squamous cell carcinoma (LA OSCC),,,,,,,Tislelizumab (200mg) and platinum-doublet chemotherapy[albumin-bound paclitaxel (240 mg/m2) plus cisplatin (70 mg/m2)] on day 1 Q3W for three cycles,"eligible patients with untreated locally advanced, resectable OSCC (T3-4bN0-3M0; stage III-IVb, AJCC 8th Edition)",n=20 enrolled; n=20 completed neoadjuvant therapy; n=20 received surgery.,"['tislelizumab', 'albumin-bound paclitaxel', 'cisplatin']",combination,neoadjuvant,,single_arm
3392,pembrolizumab,Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer.,immune checkpoint inhibitor,"primary unresectable, incompletely resected, recurrent, or metastatic squamous cell carcinoma of the vulva",2,,immune checkpoint inhibitors could synergize with chemotherapy,PD-1/PD-L1 pathway,,,"cisplatin 40 mg/m2 weekly concurrently with intensity modulated (IM) RT, and pembrolizumab 200 mg was administered every three weeks for a total of 12 cycles","patients with primary unresectable, incompletely resected, recurrent, or metastatic squamous cell carcinoma of the vulva undergoing RT. Patients who had received prior chemotherapy were also eligible.",n=24 enrolled; data cutoff 01/22/2025.,"['cisplatin', 'pembrolizumab']",add on,"primary unresectable, incompletely resected, recurrent, or metastatic",,single_arm
3065,cetrelimab,C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC).,anti-PD-1,aggressive variant prostate cancers (AVPC),2,,anti-PD-1,PD-1,,Nira 300mg BID,Nira 300mg BID + Cet,men with CRPC meeting ≥ 1 of 9 AVPC criteria and ECOG performance status 0-2,"120 patients started induction therapy, of whom 60 were randomized 1:1 to the niraparib arm (n=30) or the niraparib + cetrelimab arm (n=30); post-randomization median follow up was 20.5 mo.","['niraparib', 'cetrelimab']",add on,castration-resistant prostate cancer (CRPC) with aggressive variant features,niraparib,randomized vs PARP inhibitor
17,PAXG,Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma.,,stage I-III pancreatic ductal adenocarcinoma,3,"oral, intravenous",,,,"mFOLFIRINOX (biweekly 5-fluorouracil 2400 mg/m2, irinotecan 150 mg/m2, oxaliplatin 85 mg/m2; arm B)","PAXG (oral daily capecitabine 1250 mg/m2 with biweekly cisplatin 30 mg/m2, nab-paclitaxel 150 mg/m2, gemcitabine 800 mg/m2; arm A)","patients (pts) ≤75y with resectable/borderline resectable (R/BR) pancreatic ductal adenocarcinoma (PDAC), stratified by site and CA19.9","A total of 260 eligible patients were randomly assigned to arm A (n=132) or arm B (n=128); median follow-up was 23.9 mos at the data cutoff of March 1, 2025.","['capecitabine', 'cisplatin', 'nab-paclitaxel', 'gemcitabine']",combination,pre-operative,mFOLFIRINOX,"randomized, chemotherapy"
3620,Darolutamide plus goserelin,Darolutamide plus goserelin for androgen receptor-positive salivary gland cancers: Results of phase 2 study (DISCOVARY).,,unresectable locally advanced (LA) or recurrent/metastatic (R/M) androgen receptor (AR)-positive salivary gland cancer (SGC),2,oral,combined androgen blockade (CAB),androgen receptor (AR),,,"darolutamide orally at 1,200mg daily, combined with goserelin at 3.6 mg every four weeks","Eligible patients had histologically confirmed AR-positive LA or R/M SGC, ECOG performance status (PS) 0–2, adequate organ function, and no local therapy options.","33 patients were enrolled in the combination phase, with an analysis set of n=31 for ORR; data cutoff was August 9, 2024, with a median follow-up of 13.7 mo.","['darolutamide', 'goserelin']",combination,,,single_arm
97,CART-EGFR-IL13Rα2,A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma (rGBM).,CAR T-cells,recurrent glioblastoma (rGBM),1,intracerebroventricular (ICV),bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2,EGFR and IL13Ra2,,,"A single ICV dose of CART-EGFR-IL13Rα2 cells without lymphodepleting chemotherapy, at dose levels of 5.0 x 10^6, 1.0 x 10^7, and 2.5 x 10^7 cells.",Patients with EGFR-amplified GBM that was recurrent/progressive following front-line radiotherapy were enrolled.,Total n=18 patients received treatment (n=6 per dose level); one patient had ongoing durable stable disease at 17 months at data cut-off.,,single agent,recurrent/progressive,,single_arm
2943,sasanlimab plus sacituzumab govitecan,"A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts: SSANTROP (APRO07-2022).","immunotherapy, antibody-drug conjugate",BCG-unresponsive non-muscle invasive bladder cancer (NMIBC),2,"subcutaneous, intravenous","sasanlimab (Sa), a subcutaneous (SC) anti-PD1 agent",PD-1,['Spain'],,sasanlimab (5 cy of Sa 300 mg SC on day 1 every 28 days) plus sacituzumab govitecan (7 cy of SG 10 mg/kg IV on days 1 and every 21 days),"BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts with ECOG PS 0-1, histologically confirmed BCG-unresponsive HR NMIBC, refusal or ineligibility for RC, urothelial carcinoma histology, and no prior anti-PD1/L1 or anti-CTLA-4 therapy.","Planned n=116 (modified to n=40), screened n=59, treated (safety analysis) n=41, response-evaluable n=25, 18 sites in Spain, data cut-off January 21, 2025 (safety) and December 2024 (efficacy).","['sasanlimab', 'sacituzumab govitecan']",combination,BCG-unresponsive,Pembrolizumab historical control,single_arm
1469,dostarlimab,Safety and tolerability of dostarlimab in combination antiretroviral therapy–refractory HIV-associated Kaposi sarcoma: Preliminary results from the StarKap phase Ib trial.,,HIV-associated Kaposi’s Sarcoma (KS),1b,,Programmed Cell Death-1 (PD-1) blockade may lead to anti-tumour immune reconstitution.,Programmed Cell Death-1 (PD-1),,,4-weekly dostarlimab 500 mg for 4 cycles followed by 6-weekly 1000 mg for up to 1 year,patients (pts) with well-controlled HIV and anti-retroviral (cART) refractory KS,"A total of n=13 patients were enrolled, with n=10 evaluable for safety and efficacy at cycle 4; data cut-off was 12/2024.",['dostarlimab'],single agent,cART refractory,,single_arm
3720,pembrolizumab,"Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.",antibody,locoregionally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC),2,,anti-PD-1,PD-1,,historical controls of anti-PD-1 alone,Neoadjuvant therapy consisted of SBRT 8Gy X 3 delivered over 1 week (GTV +/-3mm) followed by 3 cycles of pembrolizumab (200mg) prior to definitive surgical resection + neck dissection at week 7.,patients (pts) with resectable clinical stage III-IVA HPV-negative HNSCC who would warrant adjuvant RT per the investigators,"Enrolled n=27 pts, of whom n=22 had completed surgery at time of analysis, with a median follow-up of 8.5 mo.",['pembrolizumab'],combination,neoadjuvant,historical controls of anti-PD-1 alone,single_arm
4375,toripalimab,The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist).,,bulky unresectable stage III non-small-cell lung cancer (NSCLC),2,,,,['China'],induction chemotherapy alone for 2 cycles followed by concurrent CRT (60 Gy radiotherapy plus concurrent platinum-based chemotherapy). Patients without disease progression or grade ≥2 pneumonitis after CRT received consolidation toripalimab (240 mg every 3 weeks) for up to 12 months.,induction toripalimab (240 mg every 3 weeks) plus platinum-based doublet chemotherapy for 2 cycles followed by concurrent CRT (60 Gy radiotherapy plus concurrent platinum-based chemotherapy). Patients without disease progression or grade ≥2 pneumonitis after CRT received consolidation toripalimab (240 mg every 3 weeks) for up to 12 months.,"patients with unresectable stage III NSCLC with bulky diseases, and without EGFR/ALK alterations. Bulky diseases were defined as primary tumor ≥5 cm in greatest dimension or metastatic lymph nodes ≥2 cm in shortest diameter.","52 patients were randomized to the induction toripalimab group (n=27) or chemo group (n=25); median follow-up was 13.1 mo at the January 15th, 2025 data cutoff.","['toripalimab', 'platinum-based doublet chemotherapy']",add on,,induction chemotherapy alone,"randomized, chemotherapy"
327,camrelizumab,"Camrelizumab plus nab-paclitaxel and cisplatin as first-line treatment for metastatic triple-negative breast cancer: A prospective, single-arm, open-label phase II trial.",monoclonal antibody,first-line treatment for metastatic triple-negative breast cancer (mTNBC),2,intravenously,humanized monoclonal antibody against PD-1,PD-1,,,"camrelizumab (200 mg D1), nab-paclitaxel (125 mg/m2 D1,D8) and cisplatin (75 mg/m2 D1) intravenously every 3 weeks",Patients with untreated mTNBC; median age was 51 years; 46.7% of patients had three or more metastatic sites; 78.9% of patients had visceral involvement; 82.2% of patients had taxanes exposure.,"A total of 90 patients were enrolled; data cutoff was July 10th 2024, with a median follow-up of 18.1 mo.","['camrelizumab', 'nab-paclitaxel', 'cisplatin']",add on,first-line,,single_arm
65,exemestane + ovarian function suppression,15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.,,premenopausal hormone receptor-positive early breast cancer (BC),3,,aromatase inhibitor-containing adjuvant endocrine therapy,aromatase,,5y tamoxifen + ovarian function suppression (T+OFS) or 5y tamoxifen (T) alone,5y exemestane + ovarian function suppression (E+OFS),premenopausal women with HR+ early BC,SOFT and TEXT enrolled 2660 women in TEXT and 3047 in SOFT (intention-to-treat populations); the TEXT+SOFT combined analysis compared E+OFS (n=2346) vs T+OFS (n=2344); median follow-up was 15y in SOFT and 16.6y in TEXT.,"['exemestane', 'ovarian function suppression']",combination,adjuvant,tamoxifen (T)+OFS or T alone,randomized / endocrine therapy
1118,metformin,Phase I/II study of maintenance therapy with metformin and temozolomide for newly diagnosed glioblastoma.,small molecule,maintenance therapy for newly diagnosed glioblastoma,1/2,,induces the differentiation of stem-like glioma-initiating cells and suppresses tumor formation via AMPK-FOXO3 activation,AMPK-FOXO3,,,"MF monotherapy for 14 days, followed by six cycles of TMZ combined with daily MF (2,250 mg) for 365 days.","Patients aged 20–74 years with supratentorial GBM, Karnofsky Performance Status ≥ 70, and a history of initial chemoradiotherapy with TMZ were eligible.","A total of 22 patients were enrolled in 5 hospitals, with 21 patients receiving the treatment combination.","['metformin', 'temozolomide']",add on,maintenance,,single_arm
450,capecitabine with cemiplimab,Phase I trial of capecitabine with cemiplimab in patients with hormone receptor–positive metastatic breast cancer.,,hormone receptor positive (HR+) HER2 negative metastatic breast cancer (MBC),1,"intravenous, oral","Capecitabine has shown immunomodulatory activity by increasing interferon-gamma from activated tumor infiltrating immune cells, thus inducing PD-L1 expression.",PD-L1,,,A fixed dose of cemipilimab IV 350 mg on day 1 in combination with Capecitabine orally twice daily for 14 days on and 7 days off starting on day 3 of a 21-day cycle. Patients were started at capecitabine 800 mg/m2 and if well tolerated then increased to 1000 mg/m2.,Patients with HR+/HER2- MBC without prior chemotherapy or immunotherapy who had progression on prior endocrine treatment (1 to 6 lines) and prior treatment with a CDK4/6 inhibitor (92.3%).,Thirteen eligible patients (n=13) were enrolled.,"['cemiplimab', 'capecitabine']",combination,Post-endocrine therapy,,single_arm
2641,lenvatinib,"TACE with or without lenvatinib as adjuvant therapy for HCC with microvascular invasion (MVI) or portal vein thrombus (Cheng’s I/II): A single-center, prospective, non-randomized cohort study.",targeted therapies,adjuvant therapy for HCC with microvascular invasion (MVI) or portal vein thrombus (Cheng’s I/II) after radical resection,,oral,,,['China'],TACE alone,lenvatinib (8mg qd for weights < 60kg and 12mg qd for weights≥60kg) in combination with TACE (Len+TACE),Patients who underwent radical resection of HCC with MVI or PVTT (Cheng's Classification I/II).,"A total of 74 patients were included, with 37 patients in the Len+TACE group and 37 in the TACE group.",['lenvatinib'],add on,adjuvant,TACE alone,"randomized, TACE"
1895,mFOLFIRINOX,mFOLFIRINOX efficacy as rescue regimen for patients with metastatic refractory colorectal cancer: The RE-PLAY trial.,,metastatic refractory colorectal cancer (mCCR),2,continuous infusion,,,,,"The mFOLFIRINOX regimen consisted of 5-FU (2400 mg/m², continuous infusion over 46 hours), Ox (85 mg/m², D1), Ir (150 mg/m², D1), and leucovorin (200 mg/m², D1), administered every 14 days.","Eligible pts had mCCR with documented progression after treatment with doublets or sequential monotherapy regimens containing F, Ox, and Ir. Pts with RAS wild-type tumors were required to be refractory to anti-EGFR therapy.","25 pts were enrolled (ITT n=25), with 22 pts receiving at least one cycle of treatment; median follow-up was 6.8 mo.","['5-FU', 'oxaliplatin', 'irinotecan', 'leucovorin']",combination,refractory,,single_arm
1608,TSN1611,"The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.",small molecule,advanced solid tumors harboring KRAS G12D mutation,1/2,oral,TSN1611 is a novel small molecule KRAS G12D inhibitor targeting both active (GTP-bound) and inactive (GDP-bound) forms of KRAS G12D protein.,KRAS G12D,,,"Pts received oral TSN1611 twice daily (BID), until disease progression, unacceptable toxicity, or patient withdrawal. Doses ranged from 50 to 600 mg BID.","patients (pts) with advanced solid tumors harboring KRAS G12D mutation, with a median age of 61 years and a median of 3 prior lines of systemic therapy.","As of Jan 05, 2025, n=18 patients were enrolled and received TSN1611, with n=13 evaluable for response.",['TSN1611'],single agent,refractory,,single_arm
2329,surufatinib plus KN046,"Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): A single-arm, phase 1b/2 trial.","kinase inhibitor, bispecific antibody",first line (1L) advanced pancreatic cancer (PC),1b/2,"oral, intravenous","K is a humanized bispecific antibody targeting PD-L1/CTLA-4, while S is a kinase inhibitor of VEGFR1-3, FGFR1 and CSF-1R with immune-regulatory potential.","PD-L1, CTLA-4, VEGFR1-3, FGFR1, CSF-1R",,,"oral surufatinib (S) at escalating dose starting from 200 mg qd (RP2D determined as 250mg qd), plus intravenous KN046 (K) at 5 mg/kg on day 1, and GnP (Gemcitabine and nab-paclitaxel) chemotherapy on days 1 and 8 at 21-day cycles.",enrolled pts with unresectable locally advanced or metastatic PC who were eligible for 1L treatment.,"18 patients were enrolled (n=9 in phase 1b, n=16 evaluable) with a median follow-up of 7.43 mo as of the Dec 19th, 2024 data cutoff.","['surufatinib', 'KN046', 'gemcitabine', 'nab-paclitaxel']",add on,1L,,single_arm
1698,tasurgratinib (E7090),A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.,,advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration,2,oral,selective inhibitor of FGFR1-3 tyrosine kinase,FGFR1-3 tyrosine kinase,,,tasurgratinib 140 mg QD,patients (pts) with advanced solid tumors harboring FGFR gene alterations,"Registered n=46; full analysis set n=41 (Group A n=10, Group B n=15, Group C n=15, Group D n=1); target enrollment n=10 (Group A), n=15 (Group B), n=15 (Group C), n=1-5 (Group D).",['tasurgratinib'],single agent,advanced solid tumors,,single_arm
3719,metronomic therapy (methotrexate and celecoxib),Comparative impact of metronomic therapy (methotrexate and celecoxib) and cisplatin-based radiochemotherapy on health-related quality of life in tracheostomized head and neck cancer patients: A comparative analysis.,,"Tracheostomized patients with metastatic, or advanced head and neck squamous cell carcinoma (H&N SCC).",,,,,,cisplatin-based Radiochemotherapy,metronomic therapy (methotrexate and Celecoxib),"Tracheostomized patients aged 18 years or older, diagnosed with metastatic, or advanced head and neck squamous cell carcinoma (H&N SCC). Eligibility criteria required a Karnofsky Performance Score of at least 70.",A total of 50 patients were enrolled (metronomic: n=25; cisplatin: n=25).,"['methotrexate', 'celecoxib']",combination,advanced/metastatic,cisplatin-based Radiochemotherapy,randomized vs cisplatin-based radiochemotherapy
1825,Debio 0123,In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide.,,SCLC participants that recurred or progressed after previous platinum treatment,1/2,oral,highly selective WEE1 kinase inhibitor,WEE1 kinase,,,Debio 0123 administered in combination with carboplatin and etoposide,adult SCLC participants that recurred or progressed after previous platinum treatment,,"['Debio 0123', 'carboplatin', 'etoposide']",combination,recurred or progressed after previous platinum treatment,,single_arm
2747,Cabozantinib,"Second interim analysis of CABONEN: An international, multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3.",tyrosine kinase inhibitor,"advanced, low proliferative NEN G3",2,,tyrosine kinase inhibitor,tyrosine kinase,,,Cabozantinib,"NEN G3 patients with a Ki67 between 20% and 60%; 26.7% were therapeutically naïve, 28.9% had 1 prior therapy, and 44.4% had 2 or more prior therapeutic lines.",Planned n=45; enrolled n=45.,['Cabozantinib'],single agent,"Mixed lines including treatment-naïve, 1 prior therapy, and 2 or more prior lines",,single_arm
1049,metformin,Neuro-oncology anywhere: Preliminary results from a decentralized clinical trial aimed at improving neurocognitive outcomes in patients with CNS malignancy.,small molecule,neurocognitive outcomes in patients with CNS malignancy,,oral,targeting radiation-related toxicity,,,health promotion with a wearable device,health promotion with a wearable device +/- metformin,patients who have received intracranial radiation for primary and secondary brain tumors,"A total of 54 of 100 planned participants have enrolled (n=27 per arm) as of the data cut-off date of January 27, 2025.",['metformin'],add on,Post-intracranial radiation,health promotion with a wearable device,randomized vs. health promotion with wearable device
14,anlotinib,"Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).",VEGFR-TKI,unresectable metastatic colorectal cancer (mCRC),3,oral,oral VEGFR-TKI,VEGFR,['China'],"bevacizumab (7.5mg/kg, IV, day 1), combined with oxaliplatin (130mg/m², IV, day 1) and capecitabine (1000mg/m², BID, days 1-14) in 3-week cycles. After 4-8 induction cycles, maintenance therapy with bevacizumab plus capecitabine continued until progression/unacceptable toxicity.","anlotinib (12mg, QD, days 1-14) combined with oxaliplatin (130mg/m², IV, day 1) and capecitabine (850mg/m2, BID, days 1-14) in 3-week cycles. After 4-8 induction cycles, maintenance therapy with anlotinib plus capecitabine continued until progression/unacceptable toxicity.",treatment-naïve RAS/BRAF wild-type mCRC patients with MDT-assessed unresectable metastases,"A total of 748 patients were randomized in the intention-to-treat population (n=373 anlotinib group, n=375 bevacizumab group) with a median follow-up of 25.10 mo.","['anlotinib', 'oxaliplatin', 'capecitabine']",add on,first-line,bevacizumab added to standard first-line chemotherapy,randomized
1152,WTX-212,Effect of erythrocyte-antibody conjugates on cancers resistant to checkpoint blockade immunotherapy: A phase I trial.,erythrocyte-antibody conjugate,advanced malignancies resistant to checkpoint blockade therapy,1,,"WTX-212 accumulates in the spleen, where it effectively remodels splenic immune landscape by expanding effector T cells and reducing the reservoir of immunosuppressive myeloid cells. These changes further reprogram the tumor microenvironment and suppress tumor growth... PD-1 blockade in the spleen using erythrocyte-antibody conjugates triggers systemic anti-tumor responses",PD-1,,,"autologous WTX-212 monotherapy in two dose cohorts (2 × 10¹¹ or 3 × 10¹¹ cells, with 6-10 mg of conjugated antibody)","heavily treated patients with 11 types of solid tumors, who had received PD-1/PD-L1 antibody-containing regimens as their last line of treatment but developed resistance","n=14 enrolled patients in two dose cohorts (2 × 10¹¹ or 3 × 10¹¹ cells); data cut-off: January 15, 2025.",['anti-PD-1 antibody'],single agent,last line of treatment after resistance to PD-1/PD-L1 antibody-containing regimens,,single_arm
1618,HSK42360,"A phase 1, multicenter, open-label study of HSK42360, a brain-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.",small-molecule,BRAF V600-mutated solid tumors,1,oral,"HSK42360 is a next-generation, small-molecule BRAF paradox breaker with high brain penetration. It displays significantly less paradoxical activation than approved BRAF inhibitors and spares wtBRAF-containing RAF dimers.",BRAF,,,HSK42360 (200-3600 mg/day) monotherapy was given orally.,"adult pts with advanced BRAF V600-mutated solid tumors, including those with recurrent or metastatic solid tumors or primary CNS tumors. Previous BRAF±MEK inhibitor treatment is permitted.","n=17 treated patients (n=11 efficacy evaluable) across five dose levels as of January 15, 2025.",['HSK42360'],single agent,advanced/recurrent/metastatic,,single_arm
4795,disitamab vedotin (RC48) in combination with tislelizumab and bevacizumab,Phase II study of disitamab vedotin (RC48) in combination with tislelizumab and bevacizumab in patients (Pts) with HER2 alterations locally advanced or metastatic NSCLC: Primary analysis results of RESOLUTION.,Antibody-drug conjugates (ADC),locally advanced or metastatic NSCLC harboring HER2 alterations,2,intravenously,"RC48 is a novel ADC that carries a tubulin inhibitor targeting the HER2 protein, thereby specifically recognizing and killing these cells.",HER2 protein,,,"RC48 (2.0 mg/kg, intravenously, Q3W) combined with Tislelizumab (200mg, intravenously, Q3W) and Bevacizumab (7.5 mg/kg, intravenously, Q3W)",Pts with locally advanced or metastatic NSCLC harboring HER2 alterations who have not received prior systemic therapy.,9 Pts were evaluable for efficacy from April 2024 to January 2025.,"['disitamab vedotin', 'tislelizumab', 'bevacizumab']",combination,first-line,,single_arm
4390,alectinib,Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).,,potentially resectable stage III ALK-positive NSCLC,2,,,ALK,['Italian'],,neoadjuvant alectinib for 2 cycles (8 weeks) followed by surgery and adjuvant alectinib for 24 cycles (96 weeks),"Treatment-naïve patients with potentially resectable stage III ALK-positive NSCLC, ECOG PS≤1.","A total of 33 patients were registered in 20 Italian Oncology Centers, of whom 28 (85%) underwent surgery; median follow-up was 15.2 months.",['alectinib'],single agent,neoadjuvant,,single_arm
3905,venetoclax,Venetoclax as cytoreductive therapy in high-risk acute promyelocytic leukemia: A potential alternative to anthracyclines.,,cytoreductive therapy in high-risk acute promyelocytic leukemia (APL),,,,,['India'],,"Venetoclax initiated at 100 mg and gradually increased to 400 mg over a week, added to standard ATRA (All-Trans Retinoic Acid) + ATO (Arsenic Trioxide) induction.","high-risk APL patients unsuitable for anthracycline-based induction therapy (cardiac issues, advanced age and in select patients based on physician discretion)",Ten patients (n=10) received venetoclax for a median duration of 8 days.,"['venetoclax', 'All-Trans Retinoic Acid', 'Arsenic Trioxide']",add on,induction therapy,,single_arm
1325,HLX301,"Safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.",bispecific antibody,advanced solid tumors,1a,IV,bispecific IgG1 antibody targeting PD-L1 and TIGIT,PD-L1 and TIGIT,,,HLX301 monotherapy at doses of 0.25-15 mg/kg IV Q2W,"patients with locally advanced or metastatic solid tumors who had failed or were intolerant to standard therapy, or for whom no standard therapy was available","As of Oct 27, 2023, 9 patients were enrolled (0.25 mg/kg, n=3; 1 mg/kg, n=3; 2.5 mg/kg, n=1; 5 mg/kg, n=2), with 8 efficacy-evaluable patients; median duration of treatment was 10.3 weeks.",['HLX301'],single agent,failed or intolerant to standard therapy,,single_arm
4540,iruplinalkib,"Neoadjuvant and adjuvant iruplinalkib in resectable ALK or ROS1 fusion-positive, non-small cell lung cancer (NSCLC): The preliminary results of the single-arm, exploratory Neo-INFINITY study.",,"resectable ALK or ROS1 fusion-positive, non-small cell lung cancer (NSCLC)",II,orally,,ALK or ROS1,['China'],,"Patients received neoadjuvant iruplinalkib orally at 180 mg/day (with a 7-day lead-in at 60 mg/day) for eight weeks, followed by surgery and then adjuvant iruplinalkib (the same dose and lead-in). The total treatment period was up to two years.","Adult patients with pathologically confirmed resectable ALK- or ROS1-positive NSCLC at stage IB–IIIA or IIIB (T3N2M0 only), ≥one measurable lesion via RECIST v1.1, ECOG performance status of 0 or 1.","Enrolled n=10, analysis n=8 (including n=6 ALK-positive).",['iruplinalkib'],single agent,Neoadjuvant and adjuvant,,single_arm
4719,afatinib,Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations: Heat on Beat randomized phase II study.,,first-line treatment in Japanese NSCLC patients with EGFR mutations,II,,EGFR-TKIs,EGFR,['Japan'],osimertinib (Osi),afatinib (Afa),Japanese pts with advanced or recurrent EGFR-mutant NSCLC.,"Overall, 95 eligible pts were analyzed (n=47 to Afa and n=48 to Osi) from a planned enrollment of 100 pts (n=50 per arm) at 28 sites in Japan, with a minimum follow-up of 3 years.",['afatinib'],single agent,first-line,osimertinib,randomized; EGFR-TKI
1058,pemigatinib,A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209.,,pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations,2,oral,Inhibition of FGFR1-3,FGFR1-3,['international'],,"Pemigatinib (oral, 13.5 mg on days 1-14/21)","Adults with FGFR-altered pretreated gliomas (histologically or molecularly defined GBM in cohort A; other gliomas, glioneuronal tumors, and neuronal tumors in cohort B) with tumors harboring a FGFR1-3 fusion/rearrangement or mutation that had recurred/progressed after ≥1 prior therapy.","A total of 83 patients were enrolled (n=74 in cohort A, n=9 in cohort B) with a data cutoff of September 27, 2024.",['pemigatinib'],single agent,2L+,,single_arm
1372,EGL-001,"EGL-121, a first-in-human phase 1/2 trial of EGL-001 in adult patients with selected advanced and/or metastatic solid tumors.",therapeutic agent,selected advanced and/or metastatic solid tumors,1/2,,designed to provide checkpoint inhibition by antagonizing the CTLA-4-CD80/86 interaction while selectively depleting intratumoral Tregs by downregulating CD25 and inhibiting IL-2 signaling specifically within these cells.,"CTLA-4, CD25, IL-2 signaling","['France', 'Spain']",,"Part 1 (Phase 1) dose escalation of EGL-001 administered as a single agent (from 0.3 mg/kg to 12 mg/kg), and in combination with pembrolizumab treatment... Part 2 (Phase 2) dose expansion of EGL-001 administered at the selected doses as monotherapy and/or in combination therapy with anti-PD(L)1.","adult patients with selected advanced and/or metastatic solid tumors... who have initially benefited (secondary resistance) from an ICI treatment as monotherapy or in combination as SoC as defined by a CR, PR, or SD ≥3 months as best response by RECIST Version 1.1.","Trial conducted at eight sites in France and Spain; as of January 2025, the first 3 dose escalation cohorts (0.03, 0.1, 0.3 mg/kg) have been completed.","['EGL-001', 'pembrolizumab']",single agent and combination,Patients with secondary resistance to prior ICI treatment,pembrolizumab (in combination arm),single_arm
4334,belantamab,Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial.,monoclonal antibody,relapsed/refractory multiple myeloma (RRMM),1,intravenous,Belantamab (GSK2857914) is the naked BCMA mAb without MMAF,BCMA,,,"belantamab 300, 900 or 2000 mg IV Q2W","patients (pts) with RRMM with ≥3 prior lines of therapy. Median age was 76 y (range, 42-86 y), 17 of 18 pts were triple-class exposed, and 2 of 18 pts had prior BCMA-targeted therapy.","Total enrolled n=18 across 3 cohorts (n=6 each); data cutoff Aug 23, 2024; median duration of exposure 63.5 days.",['belantamab'],single agent,≥3 prior lines of therapy,,single_arm
5327,naxitamab,"The combination of naxitamab with or without sintilimab (anti-PD-1) for the treatment of refractory/progressive neuroblastoma: A prospective, non-randomized, multicenter trial.",humanized anti-GD2 monoclonal antibody,refractory or progressive neuroblastoma (NB),,,"Naxitamab, a humanized anti-GD2 monoclonal antibody",GD2,['China'],naxitamab+GM-CSF (n = 6) and naxitamab+GM-CSF+chemotherapy (n = 12),naxitamab+GM-CSF+sintilimab (n = 2) and naxitamab+GM-CSF+chemotherapy+sintilimab (n = 14),"patients with refractory or progressive NB, with a median age of 3.8 years. 5 (14.7%) were diagnosed with MYCN-amplified NB, while 27 (79.4%) presented with non-amplified MYCN. Prior to enrollment, 5 patients had received autologous stem cell transplantation, while 1 patient had undergone allogeneic stem cell transplantation.","A total of 34 patients were enrolled, with treatment regimens including naxitamab+GM-CSF+sintilimab (n=2), naxitamab+GM-CSF (n=6), naxitamab+GM-CSF+chemotherapy (n=12), and naxitamab+GM-CSF+chemotherapy+sintilimab (n=14); efficacy was evaluable in 25 patients. The median follow-up time was 14.8 mo.","['naxitamab', 'sintilimab', 'GM-CSF', 'chemotherapy']",combination,refractory or progressive disease,The study compared outcomes for patients treated with sintilimab versus those without sintilimab within different treatment regimens.,single_arm
41,panitumumab,Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.,anti-EGFR monoclonal antibodies,chemorefractory metastatic colorectal cancer (mCRC) patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA),2,,anti-EGFR monoclonal antibodies,EGFR,['Italian'],regorafenib (rego) followed by panitumumab (pani) after progression (arm B),panitumumab (pani) followed by regorafenib (rego) after progression (arm A),"chemorefractory RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) pts, who previously derived benefit from first-line anti-EGFR-containing regimens, then received at least one intervening anti-EGFR-free line of treatment, and were prospectively selected for the absence of RAS and BRAF mutations in their ctDNA.","428 pts screened, 213 randomized (arm A n=106, arm B n=107) from 37 Italian centers; analysis sets for 2nd progression included n=75 (arm A) and n=70 (arm B), and per protocol population n=68/69 (A/B); median follow-up 23.5 mo.",,sequential,chemorefractory,regorafenib,randomized vs regorafenib
233,disitamab vedotin combined with penpulimab,"An exploratory clinical study investigating the neoadjuvant treatment of HER2-low expressing, stage II-III breast cancer with disitamab vedotin combined with penpulimab (RCVDBCIIR005).",antibody-drug conjugate (ADC),neoadjuvant treatment for HER2-low early or locally advanced breast cancer,2,intravenous,"Disitamab Vedotin, a novel HER2-targeted antibody-drug conjugate (ADC), and Penpulimab, an anti-PD-1 monoclonal antibody","HER2, PD-1",['China'],,"Disitamab Vedotin (2.0 mg/kg IV) and Penpulimab (200 mg IV) every 3 weeks for a total of 6 cycles, followed by surgery.","patients with newly diagnosed HER2-low expressing (IHC 1+ or 2+ without amplification by FISH), stage II-III breast cancer","A total of 20 patients were enrolled, with an analysis set of n=16.","['disitamab vedotin', 'penpulimab']",combination,neoadjuvant,,single_arm
3742,lenvatinib plus pembrolizumab,A phase II study of lenvatinib plus pembrolizumab in patients with recurrent/metastatic salivary gland cancers.,"multikinase inhibitor, programmed death-1 (PD-1) inhibitor",recurrent/metastatic (R/M) salivary gland cancers (SGCs) (non-ACC histologies),2,"oral, intravenously","Based on the hypothesis that VEGFR inhibition can enhance immune checkpoint-induced responses against SGCs, we conducted a phase II trial of the multikinase inhibitor lenvatinib (len) plus the programmed death-1 (PD-1) inhibitor pembrolizumab (pem)","VEGFR, PD-1",,,Len 20 mg oral daily and pem 200 mg intravenously every 3 weeks,Patients (Pts) with R/M SGC (except ACC) were enrolled. RECIST v1.1 measurable disease was required; prior therapies were allowed. Pts with acinic cell carcinoma (AcCC) were required to have progression of disease (PD) or worsening disease-related symptoms.,"A total of 27 patients were enrolled, with 26 evaluable for study endpoints, as of the data cut-off on 1/20/25.","['lenvatinib', 'pembrolizumab']",combination,recurrent/metastatic,,single_arm
6108,"radiotherapy, doxorubicin, and PD-1 antibody (Sintilimab)",A phase Ib/II trial of radiotherapy combined with doxorubicin and PD-1 antibody for localized high-risk limbs and trunk soft tissue sarcomas.,antibody,localized high-risk limbs and trunk soft tissue sarcomas,Ib/II,i.v.,PD-1 antibody,PD-1,,,"Participants will receive RT (BED = 50-60 Gy), combined with DOXO and PD-1 antibody (Sintilimab, SIN 200 mg, Day 1) every three weeks for four cycles prior to surgery. In Phase Ib (3+3 design), patients will receive Pegylated liposomal doxorubicin (PLD, 37.5 mg/m² or 30 mg/m², i.v., Day 1). In Phase II, DOXO will be administered as PLD at RP2D or as Doxorubicin Hydrochloride (Adriamycin, ADM, 75 mg/m² i.v., Day 1).",patients with localized high-risk STSs,"A total of 33 of a planned 52 patients were enrolled, with 28 radiologically evaluable and 24 pathologically assessable.","['doxorubicin', 'sintilimab']",combination,preoperative,,single_arm
209,abemaciclib and niraparib,A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive and HER2 negative breast cancer.,inhibitor,neoadjuvant therapy in hormone receptor positive and HER2 negative breast cancer,1,PO,"Abemaciclib is a cyclin dependent kinase 4/6 inhibitor... Niraparib is a poly-ADP-ribose polymerase inhibitor (PARPi)... In preclinical data, treatment with abemaciclib sensitizes tumors to DNA damaging agents such as PARPi.","cyclin dependent kinase 4/6, poly-ADP-ribose polymerase (PARP)",,,"dose level 1 (DL1) consisting of abemaciclib 150 mg PO BID and niraparib 100 mg PO daily, and DL2 of abemaciclib 150 mg PO BID and niraparib 200 mg PO daily","Pts aged ≥18 years with biopsy-proven stage I-III HRBC (ER ≥1%, PR ≥1%, HER2 non-amplified) planned for NAT were eligible for this study.","A total of n=8 pts were enrolled (n=3 at DL1), with n=5 completing 2 cycles for disease evaluation; median follow-up was 3 years.","['abemaciclib', 'niraparib']",combination,neoadjuvant,,single_arm
2248,gemcitabine plus cisplatin,Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.,chemotherapy,Biliary Tract Cancer (BTC) and (incidental) Gallbladder Carcinoma ((I)GBC),3,,,,,direct surgery followed by adjuvant treatment according to investigators choice (Arm B),neoadjuvant (perioperative) systemic chemotherapy (Gemcitabine + Cisplatin 3 cycles pre- and post-surgery) followed by radical surgery (Arm A),patients (pts) with localized or locally advanced resectable non metastatic biliary tract cancer (intra-/extrahepatic cholangiocarcinoma ICC/ECC; GBC in front of radical liver resection),"Randomized n=68 (ITT Arm A n=32, ITT Arm B n=30); median follow-up 11.8 mo.","['gemcitabine', 'cisplatin']",combination,Neoadjuvant / Perioperative,direct surgery followed by adjuvant treatment,randomized vs. direct surgery
1201,allogeneic double-negative T cells,Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: A phase I trial.,cell therapy,preventing relapse in high-risk AML patients after allo-HSCT,I/II,infusion,The dual ability of DNTs to suppress GvHD while preserving the graft-versus-leukemia effect,,,,Two dosage groups: 1×10^8 DNTs/kg and 1.5×10^8 DNTs/kg. Each patient received three infusions at one-month intervals without prior lymphodepleting chemotherapy.,Six high-risk AML patients undergoing allo-HSCT were enrolled.,"Six high-risk AML patients were enrolled (n=6) and assigned to two dosage groups; data cutoff was January 20, 2025, with a median follow-up of 17.55 mo post-HSCT.",['allogeneic double-negative T cells'],single agent,post-transplant setting,,single_arm
3925,Venetoclax,"Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes.",,newly diagnosed AML patients unfit for intensive chemotherapy,,,,CYP3A,,VEN 400 mg without posaconazole,VEN 50 mg with posaconazole,31 AML patients unfit for intensive chemotherapy.,"Total enrolled n=31 (VEN50 cohort, n=20; VEN400 cohort, n=11).","['venetoclax', 'posaconazole']",combination,newly diagnosed,venetoclax 400mg without posaconazole,randomized vs venetoclax
6221,corticosteroid therapy,"A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors.",,mild pneumonitis associated with immune checkpoint inhibitors,,,,,['Japan'],6-week corticosteroid treatment,3-week corticosteroid treatment,"Patients with mild immune-related pneumonitis (grade 1 or 2), with a median age of 72 years, 81% men, and 73% with grade 2 pneumonitis at baseline.","A total of n=106 patients were randomized, with n=105 in the ITT population (n=51 in the 3-week group, n=54 in the 6-week group) from 22 institutions in Japan.",['corticosteroid'],single agent,,6-week corticosteroid treatment,randomized vs corticosteroid treatment
1292,LB1410,"Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.",bispecific antibody,advanced solid tumors or lymphoma,1,intravenous,recombinant humanized anti-PD-1/TIM-3 bispecific antibody (BsAb),TIM-3/PD-1,,,LB1410 at dose cohorts ranging from 0.001 mg/kg to 20 mg/kg IV Q2W.,Eligible patients were ≥18 years old with ECOG PS 0-1 and advanced solid tumors; 76.9% of enrolled patients had solid tumors that had failed standard therapies and were resistant or refractory to anti-PD-1/PD-L1 treatments.,"Total enrolled n=79; response-evaluable n=66; data cut-off January 15, 2025.",['LB1410'],single agent,resistant or refractory to anti-PD-1/PD-L1 treatments,,single_arm
3359,pembrolizumab and lenvatinib,A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).,"PD-1 inhibitor, anti-angiogenic tyrosine kinase inhibitor",recurrent or persistent clear cell ovarian carcinoma (CCOC),2,"intravenous, oral",the combination of the PD-1 inhibitor pembrolizumab with the anti-angiogenic tyrosine kinase inhibitor lenvatinib,PD-1,,,pembrolizumab 200 mg IV every 3 weeks and lenvatinib 20 mg daily,"Pts with clear cell ovarian carcinoma (CCOC) and measurable disease who could have received an unlimited number of prior therapies; prior bevacizumab and immune checkpoint inhibitors were allowed, but prior lenvatinib was exclusionary. Malignant bowel involvement was not allowed.","Enrolled n=30 (stage 1 n=18, stage 2 n=13); data cut-off 22-Oct-2024; median follow-up 9.72 mo.","['pembrolizumab', 'lenvatinib']",combination,recurrent or persistent,,single_arm
1598,A2B694,EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).,CAR T therapy,solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH),1/2,infusion,"an autologous, logic-gated Tmod CAR T therapy targeted to MSLN, which is normally expressed in the mesothelium and can be upregulated in many solid tumors. A2B694 is designed to overcome challenges of on-target, off-tumor toxicity that have limited other MSLN-targeted approaches by combining a CAR-activating receptor targeting MSLN with a blocker CAR that recognizes HLA-A*02, to distinguish between normal and tumor cells",MSLN,,,A2B694 infusion following lymphodepletion. Dose escalation started at 1x10^8 Tmod positive cells (DL 1) and will increase up to 14x10^8 in combination with low-dose IL-2 (DL 5).,"Adults with recurrent unresectable, locally advanced, or metastatic cancers with MSLN expression who have progressed after standard-of-care therapy, with enrolled participants having ovarian cancer, pancreatic cancer, or non-small cell lung cancer and a median of 4 prior lines of therapy.","Enrolled n=5, efficacy evaluable n=5; data cut-off Jan 15, 2025; follow-up up to 7.5 mo.","['A2B694', 'IL-2']",combination,post standard-of-care,,single_arm
3924,RD06-03,A phase I study of allogeneic anti-CD19 CAR-T therapy for patients with CD19+ relapsed/refractory acute B-lymphoblastic leukemia.,cell therapy,CD19+ relapsed/refractory acute B-lymphoblastic leukemia (R/R B-ALL),1,infusion,"an allogeneic CAR-T product engineered with TCR/Gene-X knockout and NK inhibitory molecule overexpression, exhibiting resistance to allogeneic rejection and enhanced anti-tumor effects without inducing graft-versus-host disease (GvHD).",CD19,,,"RD06-03 at dose levels (CAR+ T cells/kg) of DL1: 1×10^5, DL2: 3×10^5, DL3: 5×10^5 and EDL (exploratory dose level): 6.5×10^5, following lymphodepletion with fludarabine (30mg/m^2/day) and cyclophosphamide (500mg/m^2/day) for 3 days before CAR-T infusion.",Patients aged 3-70 years with CD19+ R/R B-ALL.,"Total enrolled n=6 (DL1: n=1, DL2: n=3, DL3: n=1, EDL: n=1) as of data cut-off December 15, 2024, with a median follow-up of 128 days.",['RD06-03'],single agent,relapsed/refractory,,single_arm
7,Niraparib,Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.,small molecule,metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes,3,oral,highly selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP)-1/2,poly (ADP-ribose) polymerase (PARP)-1/2,,PBO + AAP (placebo plus abiraterone acetate 1000 mg plus prednisone 5 mg),dual-action tablet (NIRA 200 mg + abiraterone acetate 1000 mg) plus prednisone 5 mg,"Pts with germline or somatic HRR gene alterations (BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, PALB2, RAD51B, RAD54L) with metastatic castration-sensitive prostate cancer (mCSPC) who had received ≤6 mo of androgen deprivation therapy (ADT) ± ≤6 cycles of docetaxel (DOC) ± ≤45 d of AAP with metastatic disease extended beyond lymph nodes.",A total of 696 pts were randomized to NIRA + AAP (n=348) or AAP (n=348); median follow-up is 30.8 mo; data cutoff was 7 Jan 2025.,"['niraparib', 'abiraterone acetate', 'prednisone']",add on,metastatic castration-sensitive prostate cancer (mCSPC),PBO + AAP (placebo plus abiraterone acetate plus prednisone),randomized vs abiraterone acetate plus prednisone
4860,Gegen Qinlian Tablets,"Efficacy and safety of Gegen Qinlian tablets in attenuating immune-related adverse events in NSCLC patients: A randomized controlled, multicenter, open-label trial in China.",Tablets,Attenuating immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).,,oral,GQT might attenuate irAEs significantly and prolong the median onset time of irAEs by regulating the gut microflora and metabolites.,gut microflora and metabolites,['China'],ICI and chemotherapy,ICI and chemotherapy plus Gegen Qinlian Tablets,eligible patients with NSCLC at the first-line therapy,A total of 94 patients were enrolled and randomized (1:1) to the GQT group (n=47) or the control group (n=47); response-evaluable patients were n=45 in the GQT group and n=43 in the control group.,"['Gegen Qinlian Tablets', 'immune checkpoint inhibitor', 'chemotherapy']",add on,first-line,ICI and chemotherapy,randomized vs ICI+chemo
92,olaparib/carboplatin (OC),Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.,,neo-adjuvant treatment in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD),II,,,,,6 cycles of docetaxel/epirubicin/cyclophosphamide (75/50/500) q3w (TAC),"6 cycles of olaparib (100 mg bid, days 4-16) / carboplatin (AUC 5) q3w",Pts with HRD (Myriad genetics)-positive eTNBC,Planned sample size was 90 pts; a total of 90 pts were randomized (OC: n=46; TAC: n=44) between November 2019 and December 2023.,"['olaparib', 'carboplatin']",combination,neo-adjuvant,docetaxel/epirubicin/cyclophosphamide (TAC),randomized; docetaxel/epirubicin/cyclophosphamide
2345,serplulimab and HLX04,First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.,antibody,unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma,2,,serplulimab (anti-PD-1) and HLX04 (a bevacizumab biosimilar),PD-1,,,"serplulimab (anti-PD-1) and HLX04 (a bevacizumab biosimilar) combined with nab-paclitaxel plus gemcitabine (nab-P/Gem), followed by modified FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil; mFOLFOX)",patients with histologically or cytologically confirmed unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma,"Enrolled n=37, analyzed n=37; data cutoff November 2024, median follow-up 6.1 mo.","['serplulimab', 'bevacizumab biosimilar', 'nab-paclitaxel', 'gemcitabine', 'oxaliplatin', 'leucovorin', '5-fluorouracil']",add on,First-line,,single_arm
5023,sarilumab,"A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.",antibody,unresectable stage III or stage IV melanoma,II,,interleukin-6 (IL-6) receptor blocking antibody,IL-6 receptor,,,"Nivo/Rela 480 mg/160 mg Q4W, Ipi 1 mg/kg Q8W and Sari 200mg q2 weeks for 12 doses over 24 weeks followed by maintenance Nivo/Rela 480 mg/160 mg Q4W and Ipi 1 mg/kg Q8W.",patients with unresectable stage III or stage IV melanoma; prior adjuvant immunotherapy was allowed if > 6 months before enrollment and patients with controlled brain metastases could enroll.,n=33 treated; data cut-off 12/12/24; median follow-up 9.8 mo.,"['sarilumab', 'nivolumab', 'relatlimab', 'ipilimumab']",add on,1L,,single_arm
5052,sonidegib,"A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (laBCC): The SONIBEC trial.",,maintenance treatment for locally advanced basal cell carcinomas (laBCC) after achieving complete response (CR).,2,,,,['Italian'],,Eligible pts received tailored schedule 1 (TS1) with sonidegib 14 days on and 14 days off. Pts on TS1 who experienced grade 2-3 toxicity (except alopecia) lasting >28 days moved to TS2 (7 days on and 21 days off).,adult patients (pts) with locally advanced basal cell carcinomas (laBCC) who obtained a complete response (CR) to sonidegib regardless of the tumor’s subtype and burden.,Enrolled n=22 from 10 Italian centers; evaluable n=19; data cut-off was Jan 2025; median follow-up was 22 mo.,['sonidegib'],single agent,maintenance,,single_arm
1633,Pertuzumab plus trastuzumab (P+T),Pertuzumab plus trastuzumab (P+T) in patients (pts) with bladder (BC) and ovarian cancer (OC) with ERBB2/3 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.,,bladder (BC) and ovarian cancer (OC) with ERBB2/3 alterations (alt),2,intravenously (IV),,ERBB2/3,,,"Pertuzumab at an initial dose of 840 mg intravenously (IV), then 420 mg IV every 3 weeks and Trastuzumab at an initial dose of 8 mg/kg IV, then 6 mg/kg IV every 3 weeks until disease progression.","Eligible patients had measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment options, with bladder (BC) or ovarian cancer (OC) with ERBB2/3 alterations.",28 patients were enrolled in the bladder cancer cohort (N=28) and 28 patients were enrolled in the ovarian cancer cohort (N=28).,"['pertuzumab', 'trastuzumab']",combination,advanced cancers with no standard treatment options,,single_arm
4112,amulirafusp alfa,Phase II safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive follicular lymphoma.,monoclonal antibody,relapsed or refractory CD20-positive follicular lymphoma (FL),Ib/II,intravenously,Amulirafusp alfa (IMM0306) consists of anti-CD20 monoclonal antibody fused with the CD47 binding domain of SIRPα. It exerts potent anti-cancer efficacy by activating both macrophages and NK cells via blockading of CD47-SIRPα interaction and FcɣR engagement.,"CD20, CD47",,,amulirafusp alfa 1.6 mg/kg intravenously once a week with lenalidomide 20 mg orally once a day on Days 1 to 21 in each 28-day cycle,"Eligible patients with grade 1-3a relapsed or refractory (R/R) CD20-positive follicular lymphoma (FL) who had received previous anti-CD20 therapy, with a median of 2 prior lines of therapy.","Enrolled n=34; efficacy-evaluable n=22; data cut-off: Dec 26, 2024.","['amulirafusp alfa', 'lenalidomide']",combination,relapsed or refractory,,single_arm
15,platinum plus paclitaxel,An open label randomized non-inferiority trial comparing adjuvant platinum plus paclitaxel to platinum plus 5-FU after curative resection in high-risk penile carcinoma.,small molecule,adjuvant therapy in high-risk penile cancer,3,,,,,4 cycles of platinum plus 5-FU (PF arm),4 cycles of platinum plus paclitaxel (PP arm),"Patients with high-risk penile cancer [> 1 inguinal lymph node (LN), perinodal extension, pelvic LN, or LN > 4 cm] who underwent curative resection",A total of 49 patients were randomized (n=25 to PF arm; n=24 to PP arm) with a median follow-up of 60.1 mo.,"['platinum', 'paclitaxel']",combination,adjuvant,platinum plus 5-FU,randomized vs chemo
3614,palbociclib,Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.,small molecule,ovarian cancer (OC) with CDKN2A alterations,2,oral,oral cyclin-dependent kinase 4/6 inhibitor,cyclin-dependent kinase 4/6,,,"Palbociclib dosing was one 125 mg capsule taken orally once daily for 21 days followed by 7 days off, until disease progression.","Patients with advanced ovarian cancer (OC) with CDKN2A alterations, measurable disease, ECOG performance status (PS) 0-2, adequate organ function, no standard treatment options, and tumors without mutations in the RB gene.",A total of n=28 patients with ovarian cancer were enrolled.,['palbociclib'],single agent,no standard treatment options,,single_arm
291,ribociclib,Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.,,HR+/HER2+ advanced breast cancer,IB/II,,CDK4/6 inhibitors,CDK4/6,['South Korea'],,"ribociclib (RPIID: 600 mg QD) with fixed doses of letrozole (2.5 mg QD) and trastuzumab (8 mg/kg loading, then 6 mg/kg every 3 weeks)",Eligible patients were HR+/HER2+ ABC with no prior systemic therapy for metastatic disease.,"Phase IB (n=13) and Phase II (n=77) were conducted across 17 academic institutions in South Korea, with a median follow-up of 15.8 mo.","['ribociclib', 'letrozole', 'trastuzumab']",combination,first-line,,single_arm
107,cadonilimab,Neoadjuvant cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) plus chemotherapy in early or locally advanced triple-negative breast cancer: A single-arm phase II trial (CABIN study).,bispecific antibody,Neoadjuvant treatment for stage IA-IIIC triple-negative breast cancer (TNBC).,II,,bispecific PD-1/CTLA-4 antibody,PD-1/CTLA-4,,,cadonilimab (10 mg/kg) plus nab-paclitaxel (260 mg/m²) and carboplatin (AUC 4) every 3 weeks for six cycles,"patients aged 18-75 with treatment-naïve, stage IA-IIIC triple-negative breast cancer (TNBC)",A total of 29 patients were enrolled.,"['cadonilimab', 'nab-paclitaxel', 'carboplatin']",combination,neoadjuvant,,single_arm
5216,Alectinib,"Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study.",small molecule,Children and adolescents with solid or CNS tumors harboring ALK-fusions.,I/II,oral,next generation oral inhibitor of ALK-fusion proteins,ALK-fusion proteins,,,Alectinib,"Patients, less than 18 years of age, with ALK fusion-positive solid or CNS tumors for whom prior treatment had proven to be ineffective or for whom there was no satisfactory treatment available.",Total enrolled n=22; safety evaluable n=21; efficacy evaluable n=16; data cut-off July 2024.,['Alectinib'],single agent,Prior treatment ineffective or no satisfactory treatment available; includes first-line (14/22 patients had not received prior systemic therapy).,,single_arm
4727,Osimertinib plus anlotinib,"Osimertinib plus anlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent gene alterations: A single-arm, prospective, multicenter phase II study.",Tyrosine kinase inhibitor,"untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent gene alterations",2,oral,EGFR tyrosine kinase inhibitors (EGFR-TKIs),EGFR,,,"oral Osimertinib (80 mg daily) and Anlotinib (10 mg daily for 2 weeks, followed by 1 week off), repeated every 3 weeks","patients (pts) with untreated, advanced NSCLC carrying EGFR exon 19 deletions or L858R mutations plus at least one additional mutation in TP53, PI3KCA, or RB1","Enrolled n=38 as of data cut-off on June 24, 2024, with a median follow-up of 14.5 mo.","['Osimertinib', 'Anlotinib']",combination,first-line,,single_arm
5227,carboplatin with etoposide,"Phase II assessment of carboplatin with etoposide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).",chemotherapy,recurrent and primary refractory Ewing sarcoma (RR-ES),II,intravenous,,,,IFOS 15 g/m2 by continuous intravenous (IV) infusion over 5 days,IV carboplatin 400 mg/m2 day 1 and etoposide 120 mg/m2 days 1 to 3 (CE),"Patients aged at least 2 years with recurrent and primary refractory Ewing sarcoma (RR-ES), including those with refractory disease (14%), 1st recurrence (81%), or > 1st recurrence (6%).","A total of 139 patients were randomized 1:1 to IFOS (n=69) or CE (n=70), with a median follow-up of 18 mos.","['carboplatin', 'etoposide']",combination,recurrent/refractory,high dose ifosfamide (IFOS),randomized vs ifosfamide
1288,vorbipiprant,Phase I/II study of the EP4 antagonist vorbipiprant combined with anti-PD-1 immunotherapy: Safety and efficacy results in metastatic gastrointestinal non-colorectal cancers.,,metastatic non-colorectal GI cancers,I/II,oral,EP4 antagonist,EP4,,,oral vorbipiprant (90 mg twice daily) plus iv balstilimab (3 mg/kg every 2 weeks),"Twenty-seven adult patients (pts) with metastatic non-colorectal GI cancers, ECOG PS ≤1, and ≥1 prior treatment line were included in 3 cohorts (9 pts each): gastric cancer (GC) with PD-L1 Combined Positive Score (CPS) ≥5 (cohort A), GC with PD-L1 CPS < 5 (cohort B), and GI cancers other than CRC and GC (cohort C).","Enrolment of 27 patients is completed (n=9 in each of 3 cohorts); data cut-off was November 20, 2024.","['vorbipiprant', 'balstilimab']",combination,≥1 prior treatment line,,single_arm
19,Becotatug vedotin,"Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.",antibody-drug conjugate,heavily pretreated R/M NPC,2,iv,novel EGFR-targeted antibody-drug conjugate,EGFR,,"chemotherapy (capecitabine 1000 mg/m2, po, twice daily, d1-14, Q3W; or docetaxel 75 mg/m2, iv, d1, Q3W)","MRG003 (2.3 mg/kg, d1, iv, Q3W)","Eligible pts with R/M NPC had failed ≥2 lines of systemic chemotherapy and PD-(L)1 inhibitor, and were randomized to receive MRG003 (2.3 mg/kg, d1, iv, Q3W) or chemotherapy (capecitabine 1000 mg/m2, po, twice daily, d1-14, Q3W; or docetaxel 75 mg/m2, iv, d1, Q3W). Randomization was stratified according to liver metastasis (yes or no) and ECOG PS (0 or 1).",A total of 173 pts were randomly assigned to MRG003 (n=86) or chemotherapy (n=87); data cutoff 30 June 2024 (ORR/PFS) and 30 December 2024 (OS); median follow-up 13.5 mo (MRG003) and 13.6 mo (chemotherapy).,['Becotatug vedotin'],single agent,failed ≥2 lines of systemic chemotherapy and PD-(L)1 inhibitor,chemotherapy (capecitabine or docetaxel),randomized vs chemotherapy
1052,temozolomide (TMZ),Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.,,newly diagnosed non-codeleted anaplastic glioma,III,,,,,59.4 Gy radiotherapy (RT) alone,The 2x2 factorial design included three arms with temozolomide (TMZ): 59.4 Gy radiotherapy (RT) with concurrent TMZ; RT with 12 cycles of adjuvant TMZ; or RT with both concurrent and adjuvant TMZ.,adult patients with newly diagnosed non-codeleted anaplastic glioma,"Randomized n=751; intent-to-treat population with 499 events observed; IDH status determined in n=660 patients (IDHmt n=444, IDHwt n=216); median follow-up 10.9 years.",['temozolomide'],add on,newly diagnosed,radiotherapy (RT) alone,"randomized, radiotherapy"
4638,Hypoxia-responsive CEA CAR-T cells,"Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.",CAR-T cell therapy,relapsed or refractory non-small cell lung cancer (r/r NSCLC),1,intravenous,Chimeric antigen receptor (CAR)-T cell therapy has achieved significant success in targeted tumor cells eradication.,CEA,,,"intravenous CEA CAR-T cells at three dose levels (0.75×10^6, 1.5×10^6, and 3×10^6 CEA CAR-T cells/kg)",Adult metastatic NSCLC patients with relapse after ≥2 lines of treatment.,"18 patients were screened, 15 received CAR-T infusion across three dose levels (dose level 1 n=3, dose level 2 n=6, dose level 3 n=6), with a median follow-up of 5.7 mo.",['CEA CAR-T cells'],single agent,≥2 lines of treatment,,single_arm
1318,tislelizumab,A randomized controlled study of tislelizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer and the predictive value of T lymphocyte subsets for efficacy.,,locally advanced cervical cancer (LACC),,intravenously infused,,,,Concurrent chemoradiotherapy (CCRT) consisting of single-agent cisplatin at a dose of 40 mg/m2 and external irradiation using 6MV-X-ray intensity-modulated radiotherapy with a dose of 45-50Gy/25f.,"200 mg of tislelizumab intravenously infused on the first day of radiotherapy, once every 3 weeks, for 1 year, combined with concurrent chemoradiotherapy (CCRT).",patients with LACC [locally advanced cervical cancer],"A total of 53 patients were randomized to the CCRT group (n=26) or the CCRT+T group (n=27); data cutoff was January 2025, with a median follow-up of 13.7 mo in the CCRT group and 11.2 mo in the CCRT+T group.","['tislelizumab', 'cisplatin']",add on,,Concurrent chemoradiotherapy (CCRT),randomized vs. chemoradiotherapy
46,anlotinib,"Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: Results of a multicenter, double-blind, randomized phase II trial.",multi-kinase inhibitor,newly diagnosed glioblastoma (GBM),2,oral,a multi-kinase inhibitor targeting tumor angiogenesis and proliferation,tumor angiogenesis and proliferation,,"placebo alongside TMZ-based chemoradiotherapy (54–60 Gy). Patients undergo six TMZ cycles and eight placebo cycles after radiotherapy, then receiving placebo until disease progression or unacceptable toxicity.","anlotinib (10 mg/day, days 1–14 per 21-day cycle) alongside TMZ-based chemoradiotherapy (54–60 Gy). Patients undergo six TMZ cycles and eight anlotinib cycles after radiotherapy, then receiving anlotinib until disease progression or unacceptable toxicity.","Eligible patients (≥18 years, ECOG ≤2) with newly diagnosed glioblastoma, excluding those with brainstem-only tumors, prior GBM therapy, IDH1/2 mutations, or significant intracranial hemorrhage.","A total of 153 patients were randomized (n=77 anlotinib, n=76 placebo) out of a planned 150 patients; median follow-up was 27.53 mo in the anlotinib group and 31.05 mo in the placebo group.","['anlotinib', 'temozolomide']",add on,newly diagnosed,placebo,randomized vs placebo
3632,pembrolizumab in combination with dabrafenib and trametinib (DTP),Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer ( BRAF m-ATC): A multicenter phase 2 trial.,,BRAF V600E-mutated anaplastic thyroid cancer (BRAF m-ATC),2,,,BRAF V600E,['US'],,"Following a 3-6 week run-in with dabrafenib (150 mg BID) and trametinib (2 mg daily), pembrolizumab (200 mg Q3W) was added. Post-operatively, patients continued pembrolizumab (or DTP) with radiotherapy or transitioned directly to adjuvant DTP (up to 26 cycles).",patients with BRAFm-ATC stage IVB/IVC,"Enrolled n=42, analysis set n=36, from 5 US centers, with a median follow-up of 18 mo.","['pembrolizumab', 'dabrafenib', 'trametinib']",combination,Neoadjuvant,historical controls,single_arm
48,JMT101,"JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.",monoclonal antibody,metastatic colorectal adenocarcinoma (mCRC),II,,humanized IgG1 anti-EGFR monoclonal antibody [mAb],EGFR,,"regorafenib 160mg QD, days 1-21 of 28-day cycles",Arm A: JMT101 6 mg/kg + irinotecan 180 mg/m2 + SG001 240 mg Q2W; Arm B: JMT101 + irinotecan,"Patients with histologically or cytologically confirmed RAS/BRAF wild-type mCRC without MSI-H/dMMR, who had progressed after ≥ 2 prior systemic therapies.","A safety run-in (n=3) was followed by randomization of 106 patients (Arm A n=36, Arm B n=35, Arm C n=35), with 34, 35, and 34 efficacy-evaluable patients in Arms A, B, and C, respectively; data cut-off was Jan 24, 2025, with a median follow-up of 7.4 mo.","['becotatug', 'irinotecan', 'enlonstobart']",combination,3L+,regorafenib,"randomized, regorafenib"
3123,talazoparib in combination with tazemetostat,A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).,PARP inhibitor / EZH2 inhibitor,metastatic castration-resistant prostate cancer (mCRPC),Ia/Ib,,"In pre-clinical studies, EZH2 directly regulates DNA damage repair (DDR) gene expression, and inhibition of EZH2 sensitizes prostate cancer cells to genotoxic stress as induced by poly-ADP ribose polymerase (PARP) inhibition.","PARP, EZH2",,,The recommended phase 2 dose (RP2D) was talazoparib 0.75 mg daily and tazemetostat 800 mg BID. Other dose levels tested included talazoparib 0.75 mg QD + tazemetostat 600 mg BID (DL 0) and talazoparib 1 mg QD + tazemetostat 800 mg BID (DL +2).,"Eligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) had progressive disease after at least one secondary hormonal therapy and taxane-based chemotherapy, disease evaluable for response (PSA ≥ 2 ng/ml or measurable disease by RECIST 1.1) and a metastatic lesion amenable to biopsy.","Phase 1a (n=12) and Phase 1b (n=20) were conducted; 27 pts were treated at the RP2D, with 11 DLT-evaluable, 23 PSA-evaluable, and 12 with measurable disease.","['talazoparib', 'tazemetostat']",combination,progressive disease after at least one secondary hormonal therapy and taxane-based chemotherapy,,single_arm
6196,olanzapine,Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy-induced nausea and vomiting (RINV): CTRI/2022/01/039723.,,prevention of radiotherapy-induced nausea and vomiting (RINV) in abdominal-pelvic radiation therapy patients,III,,,,,"matching placebo daily, along with standard care (ondansetron 4mg twice daily)","5mg olanzapine daily, along with standard care (ondansetron 4mg twice daily)","patients undergoing radiotherapy (RT) [Eligibility: >18 yrs, abdominal/pelvic RT, no prior RT history]","Screened n=683, randomized n=301 (placebo n=153, experimental/olanzapine n=148).","['olanzapine', 'ondansetron']",add on,,placebo,"randomized, placebo"
6202,romiplostim,"Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).",thrombopoietin receptor agonist,"chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers",3,subcutaneous,thrombopoietin receptor agonist,thrombopoietin receptor,,placebo (PBO) for 3 chemotherapy cycles,"romiplostim (ROMI) for 3 chemotherapy cycles, started at 2 μg/kg subcutaneous weekly, adjusted weekly by 1 μg/kg up to 10 μg/kg to target Plt ≥100×10^9/L","patients receiving oxaliplatin-based multiagent regimens for GI cancers with persistent CIT, ie platelets (Plt) ≤85×10^9/L on day 1 of a scheduled chemotherapy cycle","Randomized N=165 (n=109 ROMI, n=56 PBO) from 55 sites in 14 countries.","['romiplostim', 'oxaliplatin']",add on,,placebo (PBO),randomized vs placebo
2877,pembrolizumab,Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC).,monoclonal antibody,adjuvant treatment of clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence,3,intravenous,,PD-1,,pbo IV Q3W for ~1 yr (17 cycles),pembro 200 mg IV Q3W for ~1 yr (17 cycles),"Adults with ccRCC with intermediate-high (pT2 Gr 4 or sarcomatoid, or pT3 any Gr, N0 M0) or high (pT4 any Gr, N0 M0, or any pT and Gr, N+ M0) risk of recurrence or M1 with no evidence of disease (NED) who had nephrectomy and/or metastasectomy ≤12 wks prior to randomization.",A total of 994 pts were randomized to pembro (n=496) or pbo (n=498); data cutoff was 25 Sept 2024 with a median follow-up of 69.5 mo.,['pembrolizumab'],single agent,adjuvant,placebo (pbo),randomized placebo
1088,B7H3 CAR-T cells,A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma.,cell therapy,recurrent glioblastoma (GBM),1,intracranial,chimeric antigen receptor T cells targeting B7H3 (B7H3-CART),B7H3,,,B7H3-CART was administered via intratumoral and intraventricular Ommaya reservoirs monthly for a planned 6 months or until confirmed disease progression. Dose escalation followed a 3+3 design with a recommended phase 2 dose established at 25x10^6 cells.,patients with recurrent GBM undergoing repeat resection,"Enrolled n=11 (all had cells manufactured), evaluable n=9 (received at least one dose), with 4 patients followed up to 22 mo.",['B7H3 CAR-T cells'],single agent,recurrent setting following upfront chemoradiation and adjuvant temozolomide,,single_arm
2882,sacituzumab govitecan (SG) plus pembrolizumab (Pembro),"First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC).",,muscle-invasive bladder cancer (MIBC),2,,,,,,"4 cycles of Pembro 200 mg on D1 and SG 7.5 mg/Kg on D1 and D8, Q3W, followed by postsurgical Pembro x 13 cycles, Q3W.","Pts age ≥18 y, ECOG PS 0-1, with histologically confirmed cT2-T4N0M0 MIBC, ineligible/refusing CT, and scheduled for RC","Total planned sample size is n=48 in a 2-stage design; at the first stage n=23 were enrolled, n=40 were treated, and n=31 were efficacy evaluable.","['sacituzumab govitecan', 'pembrolizumab']",combination,neoadjuvant,,single_arm
2120,mFOLFOXIRI combined with camrelizumab and bevacizumab,"Neoadjuvant therapy with mFOLFOXIRI combined with camrelizumab and bevacizumab for microsatellite stable, locally advanced rectal cancer: A single-arm, open-label phase II study.",antibody,"microsatellite stable (MSS), locally advanced rectal cancer (LARC)",2,intravenous,PD-1 antibody,PD-1,['China'],,"intravenous administration of camrelizumab, bevacizumab, and mFOLFOXIRI for 4-6 cycles",patients with MSS-LARC aged between 18 and 70 years old,"32 patients were enrolled, with 29 patients included in the final analysis; the median follow-up time was 17.7 months.","['camrelizumab', 'bevacizumab', 'fluorouracil', 'leucovorin', 'oxaliplatin', 'irinotecan']",combination,neoadjuvant,,single_arm
73,ovarian function suppression (OFS),Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor–positive breast cancer: Results from the ASTRRA trial.,,premenopausal women with hormone-receptor (HR)–positive breast cancer,3,,,,,5 years of TAM alone (TAM-only),5 years of TAM with OFS for 2 years (TAM + OFS),premenopausal women with hormone-receptor (HR)–positive breast cancer who remain premenopausal or resume menstruation after chemotherapy,"A total of 1,282 premenopausal women were randomized 1:1; a HER2-negative cohort of n=776 was analyzed, including a high-risk subgroup of n=282. Median follow-up was 117.6 mo.","['tamoxifen', 'ovarian function suppression']",add on,adjuvant,tamoxifen (TAM) alone,randomized; tamoxifen
2892,Nivolumab plus ipilimumab,Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.,checkpoint inhibitor combination,first-line treatment of advanced renal cell carcinoma (aRCC),3,,checkpoint inhibitor combination,,,"SUN 50 mg once daily for 4 weeks on, 2 weeks off",NIVO 3 mg/kg + IPI 1 mg/kg Q3W×4 then NIVO (3 mg/kg or 240 mg Q2W or 480 mg Q4W),"Pts with clear cell aRCC, stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk.","Randomized n=1096 (NIVO+IPI n=550, SUN n=546); ITT analysis set n=1096; I/P risk n=847 (NIVO+IPI n=425, SUN n=422); FAV risk n=249 (NIVO+IPI n=125, SUN n=124); median follow-up 9 years.","['nivolumab', 'ipilimumab']",combination,first-line,sunitinib (SUN),randomized vs TKI
3668,combination doublet gemcitabine-cisplatin (GP) and PD-1 inhibitor (Toripalimab),"Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial.",PD-1 inhibitor,high-risk recurrent nasopharyngeal carcinoma (rNPC),II,,PD-1 inhibitor,PD-1,,,"All patients received 3 cycles of GP + PD-1 inhibitor, then received reRT (GTV, 60-66Gy, 1.8-2.0Gy/f) plus PD-1 inhibitor if got CR/PR (reRT group), or received another 3 cycles of GP+PD-1 inhibitor if got SD (no reRT group), finally all got 4 cycles of PD-1 inhibitor maintenance.","Eligibility criteria included diagnosed as local ± regional recurrence after ≥1 year of radical treatment, not suitable for surgery, histologic or clinically diagnosis of NPC, stage rII-IVa (AJCC/UICC 8th), PRANCIS model > 252 points.","Recruited n=68 (reRT group n=44, no reRT group n=22); median follow-up 32.7 mo.","['gemcitabine', 'cisplatin', 'Toripalimab']",combination,recurrent,,single_arm
3679,toripalimab,"Induction chemotherapy with or without toripalimab followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, open-label, randomized, controlled, phase 2 trial.",monoclonal antibody,locoregionally advanced nasopharyngeal carcinoma (LANPC),2,intravenous,,,['China'],"intravenous gemcitabine (1g/m²) on days 1 and 8, and cisplatin (80 mg/m²) on day 1, every 3 weeks for 3 cycles, followed by standard CCRT (cisplatin 100 mg/m² every 3 weeks for 3 cycles)","intravenous toripalimab (240 mg) on day 1 every 3 weeks for 3 induction cycles, plus intravenous gemcitabine (1g/m²) on days 1 and 8, and cisplatin (80 mg/m²) on day 1, every 3 weeks for 3 cycles, followed by standard CCRT (cisplatin 100 mg/m² every 3 weeks for 3 cycles)","Patients with locoregionally advanced nasopharyngeal carcinoma (LANPC) (T4NanyM0 or TanyN2/N3M0, AJCC 8th edition).","Randomized n=150 (toripalimab arm n=75; standard arm n=75) from 8 centers in China; data cut-off November 30, 2024; median follow-up 23.4 mo.","['toripalimab', 'gemcitabine', 'cisplatin']",add on,Induction,standard arm (gemcitabine and cisplatin IC followed by cisplatin concurrent chemoradiotherapy [CCRT]),"randomized, chemotherapy plus chemoradiotherapy"
5217,dose-intense irinotecan,Determining the recommended phase 2 dose (RP2D) of dose-intense irinotecan combined with IVA chemotherapy (I R IVA) in newly diagnosed very high risk rhabdomyosarcoma: A phase Ib study within the EpSSG Frontline and Relapsed Rhabdomyosarcoma study (FaR-RMS).,,newly diagnosed very high risk rhabdomyosarcoma (RMS),Ib,,,,,,"IVA (Ifosfamide 3000 mg/m² on days 1–2; vincristine 1.5 mg/m2 on days 1 and 8 and on day 15 in cycle 1 and 2 only; actinomycin D 1.5 mg/m2 on day 1) with irinotecan on days 8–12, with dose escalation from a starting dose of 20 mg/m²/day to a RP2D of 50mg/m2/day.","Patients aged >1 to ≤25 years with Very High Risk (VHR) RMS (FOXO1 fusion-positive, node-positive, Subgroup G and metastatic, Subgroup H).","Total enrolled n=22 across 4 dose levels (20 mg/m2/day, n=5; 30 mg/m2/day, n=5; 40 mg/m2/day, n=6; 50 mg/m2/day, n=6); all patients (n=22) were evaluable for DLTs.","['irinotecan', 'ifosfamide', 'vincristine', 'actinomycin D']",add on,newly diagnosed,,single_arm
390,pembrolizumab plus nab-paclitaxel,Immunotherapy vs. chemotherapy run-in followed by pembrolizumab plus nab-paclitaxel in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.,,metastatic triple negative breast cancer (mTNBC),2,,,PD-L1,,"chemotherapy run-in (cTNBC, nab-P before nab-P+pembro)","immunotherapy run-in (iTNBC, pembro before nab-P+pembro)","PD-L1 unselected mTNBC, 0-2 prior lines of chemotherapy allowed.","Total enrolled n=50 (cTNBC n=30, iTNBC n=20); median follow-up 19.9 mo.","['pembrolizumab', 'nab-paclitaxel']",combination,1L or later (0-2 prior lines),chemotherapy run-in (cTNBC) cohort,single_arm
6278,cannabis sativa extract,"IPElife: Phase III, double-blind trial of cannabis sativa extract in pain management and quality of life in patients with metastatic lung cancer.",extract,Pain management and quality of life in patients with locally advanced or metastatic lung cancer.,3,,,,,placebo,"The cannabis sativa extract administration protocol involved dose escalation, starting at 10mg/day, with titration every 5 days until the patients reached their goals or the maximum dose of 100mg/day.",patients with locally advanced or metastatic lung cancer confirmed by histopathology,Randomized n=40 (n=20 per group).,['cannabis sativa extract'],add on,,placebo,"randomized, placebo"
2958,atezolizumab,"AURORA: A single arm, multicentre, phase II clinical trial of atezolizumab immunotherapy for advanced squamous cell carcinoma of the bladder and urinary tract.",immunotherapy,advanced squamous cell carcinoma of the bladder and urinary tract,2,intravenous,,PD-L1,,,"atezolizumab (1680 mg IV, q28d) until disease progression and for up to one year if tolerated","Patients had progressive, measurable, UTSCC and ECOG performance status 0-2. Mixed histology was permitted but with no urothelial carcinoma component. One prior line of systemic chemotherapy was permitted for advanced disease but no prior immunotherapy.",Stage 1 n=19 patients assessable for response (planned total n=33); median follow-up 10.1 mo.,['atezolizumab'],monotherapy,One prior line of systemic chemotherapy was permitted for advanced disease,,single_arm
1941,cadonilimab (AK104),Neoadjuvant mFOLFOXIRI chemotherapy with or without cadonilimab versus mFOLFOX6 alone in locally advanced colorectal cancer: A randomized phase II study (OPTICAL2).,immunotherapy,locally advanced colorectal cancer (LACRC),II,,dual immunotherapy,,,"mFOLFOXIRI for 6 cycles, or mFOLFOX6 alone for 6 cycles",preoperative mFOLFOXIRI plus AK104 for 6 cycles,patients with II/III rectal ancer and locally advanced colon cancer (T3 ≥5 mm or T4),"Total randomized n=123 (n=41/arm); mITT analysis n=41 (mFOLFOXIRI+AK104), n=39 (mFOLFOXIRI), n=41 (mFOLFOX6); PP analysis n=36, n=35, n=37 respectively; data cutoff August 2024.",,add on,neoadjuvant,mFOLFOXIRI for 6 cycles or mFOLFOX6 alone for 6 cycles,"randomized, chemotherapy"
5020,OBX-115,OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.,engineered tumor-infiltrating lymphocyte (TIL) cell therapy,immune checkpoint inhibitor (ICI)–resistant advanced melanoma,1,infusion,"OBX-115 TIL are engineered to express mbIL15 regulated by the FDA-approved small-molecule drug acetazolamide (ACZ), abrogating the need for toxic high-dose IL2 after TIL infusion.",mbIL15,,,"OBX-115 manufactured from pt tumor tissue and infused after standard- or low-dose (Cy 750 mg/m2/d × 3; Flu 30 mg/m2/d × 4) lymphodepletion (LD). Oral acetazolamide (ACZ) starts day of OBX-115 infusion (QD up to 14 d), and is redosed (QD up to 7 d) every 6 wks after recovery from LD. No IL2 is administered.",patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma,"In phase 1, n=11 pts were infused, including n=6 treated at the RP2D, with a data cut-off of 01 Jan 2025 and a median study follow-up of 22.3 wks.","['OBX-115', 'acetazolamide', 'cyclophosphamide', 'fludarabine']",combination,post-ICI,,single_arm
6056,fluzoparib in combination with dalpiciclib,Phase Ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma.,,locally advanced or metastatic sarcoma,Ib/II,oral,"Poly ADP-ribose polymerase (PARP) plays a role in DNA damage repair, and PARP inhibitors can exert anti-tumor efficiency in tumors with homologous recombination repair defection (HRD). Cyclin-dependent kinase (CDK) plays an important role in cell cycle regulation. Rb is the direct substrate of CDK4/6, and Rb/E2F participates the HR-mediated DNA repair. Therefore, selective CDK4/6 inhibition can theoretically aggravate HRD and hinder DNA repair of tumor cells treated with PARP inhibitors.","PARP, CDK4/6",,,"fluzoparib (0.1 or 0.15 g po., qd, q4w) and dalpiciclib (0.1, 0.125 or 0.15 g po., qd, d1-21, q4w) continuously until progressive disease (PD) or intolerable toxicity occurred.","Patients aged 12-75 years with locally advanced or metastatic sarcomas after first-line treatment, with at least one measurable lesion according to RECIST 1.1 criteria.","n=12 in the escalation part; data cut-off Jun. 10, 2025; median follow-up 7.93 mo.","['fluzoparib', 'dalpiciclib']",combination,after first-line treatment,,single_arm
6067,catequentinib hydrochloride,A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).,small molecule,metastatic or advanced leiomyosarcoma (LMS),3,orally administered,"novel, orally administered, small molecule tyrosine kinase inhibitor",tyrosine kinase,"['US', 'UK', 'EU']","placebo, with the option of crossover to Catequentinib after confirmed Progression Disease (PD) on placebo",Catequentinib was administered in a 21-day cycle with 14 days on and 7 days off regimen.,Patients with a diagnosis of LMS requiring third or further line treatment.,"Total enrolled n=111, treated and evaluated n=110, randomized n=74 to Catequentinib and n=36 to placebo.",['catequentinib hydrochloride'],single agent,third or further line,placebo,randomized placebo
4275,"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)","Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial.",,high-risk (HR) newly diagnosed multiple myeloma (NDMM),2,,,,,,"Isa-KRd induction (6 cycles), intensification (HD-MEL+ASCT), 4 cycles Isa-KRd consolidation and 2 years Isa-KR maintenance.","Adult NDMM pts with HR disease, defined as ≥1 HR cytogenetic aberration (CA) (del(17p), t(4;14), t(14;16), ≥3 copies 1q21) in combination with ISS stage II/III.",Total included and dosed n=219 TE pts (and 26 TNE pts); MRD-analysis population n=209; data cut-off 9 Jan 2025; median follow-up 42 mo.,"['Isatuximab', 'carfilzomib', 'lenalidomide', 'dexamethasone']",add on,first-line,,single_arm
2744,PBP1510,First-in-human phase 1/2a study of PBP1510 (anti-PAUF mAb) in advanced/metastatic pancreatic adenocarcinoma: Safety results from early combination cohorts.,monoclonal antibody,advanced/metastatic pancreatic adenocarcinoma,1/2a,intravenous,PBP1510 is a first-in-class humanized anti-PAUF monoclonal antibody (mAb) with tumor-suppressing potential.,PAUF,,,"PBP1510 at 1 mg/kg (N = 3), and 3 mg/kg (N = 3) in combination with gemcitabine (1000 mg/m2) in 28-day cycles.","Key eligibility criteria include locally advanced/metastatic pancreatic adenocarcinoma, disease progression following at least 1 previous line of chemotherapy, at least 1 measurable lesion by RECIST v1.1, ECOG value of 0-1, life expectancy of ≥ 3 months, and adequate baseline organ functions.","Total enrolled n=6 (1 mg/kg cohort n=3, 3 mg/kg cohort n=3); data cut-off 6 Jan 2025.","['PBP1510', 'gemcitabine']",combination,disease progression following at least 1 previous line of chemotherapy,,single_arm
1222,ICP-B05,Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL).,humanized monoclonal antibody,relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL),1,I.V.,humanized monoclonal antibody against CCR8 with potent ADCC activity,CCR8,,,"ICP-B05 at 150 mg, 300 mg, 450 mg and 600 mg I.V. Q2W","Patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL) who failed at least 1 prior standard systemic regimen, with a median age of 46 years and a median of 3 prior lines of therapy.","A total of 13 patients were treated (n=4 at 150 mg, n=3 at 300 mg, n=3 at 450 mg, n=3 at 600 mg), with 12 patients evaluable for skin lesion assessment; data cut-off was 6th Jan, 2025.",['ICP-B05'],single agent,failed at least 1 prior standard systemic regimen,,single_arm
1274,adrixetinib (Q702),"A phase 1b/2, open-label study of selective Axl, Mer and CSF1R inhibitor adrixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: Results of a phase 1 study (QRNT-008).",tyrosine kinase inhibitor,"selected advanced solid tumors (esophageal, gastric/GEJ, hepatocellular, and cervical cancers) who have progressed on prior anti-PD-1/PD-L1 treatment",1b,oral,"selective Axl, Mer and CSF1R inhibitor for which the primary mechanism of action of tumor regression is through immune-stimulating effects.","Axl, Mer, CSF1R",,,Q702 (week on/off dosing regimen) orally at 100 mg or 120 mg doses in combination with pembrolizumab (200 mg Q3W) intravenously in 42-day cycles.,"patients with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers who have progressed on prior anti-PD-1/PD-L1 treatment.","Total n=29 patients received treatment (n=7 at 100 mg Q702, n=22 at 120 mg Q702); data cutoff was December 19th, 2024.","['adrixetinib', 'pembrolizumab']",combination,post-PD-1/PD-L1,,single_arm
